Biotech launches tend to hide the science. Stock renders, vague promises, molecules as decoration. Endura is the opposite: the RNA covalency company, building small molecules that form an enduring bond with mRNA and knock down disease-causing proteins before they're ever made.
‍

We helped a company emerging from stealth make never-before-seen science its first impression. The move was rejecting illustrated approximation in favour of the real thing: actual data, actual PyMOL renders, RNA drawn from the literature pixel by pixel. Endura launched with a deck and site where the science was legible before a single word was read.